Omar Y. Mian

Omar Y. Mian

Auto-generated profile, based on publicly available information

Omar Y. Mian

Human Biology Division, Fred Hutchinson Cancer Center, Seattle, USA

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2005 in Molecular and Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
YSYukitaka Shizukuda
Yukitaka Shizukuda
SMSatoaki Matoba
Satoaki Matoba
OMOmar Y. Mian
Omar Y. Mian
TNTammy Nguyen
Tammy Nguyen
PHPaul M. Hwang
Paul M. Hwang

1 July 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
JCJosé Batista da Costa
José Batista da Costa
EGEwan A. Gibb
Ewan A. Gibb
TBTrinity J. Bivalacqua
Trinity J. Bivalacqua
YLYang Liu
Yang Liu
HOHtoo Zarni Oo
Htoo Zarni Oo
MDMarc Dall'Era
Marc Dall'Era
Purpose: Neuroendocrine (NE) bladder carcinoma is a rare and aggressive variant. Molecular subtyping studies have found that 5% to 15% of muscle-invasive bladder cancer (MIBC) have transcriptomic patterns consistent with NE bladder cancer in the absence of NE histology. The clinical implications of this NE-like subtype have not been explored in depth.Experimental Design: Transcriptome-wide expression profiles were generated for MIBC collected from 7 institutions and clinical-use of Decipher Bladder. Using unsupervised clustering, we generated a clustering solution on a prospective training cohort (PTC; n = 175), developed single-sample classifiers to predict NE tumors, and evaluated the resultant models on a testing radical cystectomy (RC) cohort (n = 225). A random forest model was finalized and applied to 5 validation cohorts (n = 1302). Uni- and multivariable survival analyses were used to characterize clinical outcomes.Results: In the training cohort (PTC), hierarchical clustering using an 84-gene panel showed a cluster of 8 patients (4.6%) with highly heterogeneous expression of NE markers in the absence of basal or luminal marker expression. NE-like tumors were identified in 1% to 6.6% of cases in validation cohorts. Patients with NE-like tumors had significantly worse 1-year progression-free survival (65% NE-like vs. 82% overall; P = 0.046) and, after adjusting for clinical and pathologic factors, had a 6.4-fold increased risk of all-cause mortality (P = 0.001). IHC confirmed the neuronal character of these tumors.Conclusions: A single-patient classifier was developed that identifies patients with histologic urothelial cancer harboring a NE transcriptomic profile. These tumors represent a high-risk subgroup of MIBC, which may require different treatment.

22 February 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
WPWillmar D. Patino
Willmar D. Patino
OMOmar Y. Mian
Omar Y. Mian
JKJu-Gyeong Kang
Ju-Gyeong Kang
SMSatoaki Matoba
Satoaki Matoba
LBLinda D. Bartlett
Linda D. Bartlett
PHPaul M. Hwang
Paul M. Hwang
Circulating monocytes mediate inflammation in atherosclerosis and may serve as easily accessible reporters of disease. To search for markers of atherosclerosis, we compared the in vivo transcriptomes of monocytes purified from patients undergoing carotid endarterectomy and normal subjects by using the serial analysis of gene expression technique. We selected a subset of differentially expressed monocyte-specific genes and confirmed their expression levels. The Finkel–Biskis–Jinkins osteosarcoma (FOS) gene was significantly increased in patients, and the highest levels of FOS associated with patients who had previously undergone coronary revascularization. The correlation between coronary revascularization and FOS was higher than that compared with the cardiac risk marker high sensitivity C-reactive protein. In vitro inhibition of FOS using small interfering RNA and 3-hydroxy-3-methyl-glutaryl CoA reductase inhibitor simvastatin (statin) affected monocyte activation and suggested an important role in pathogenesis. Given the prominent role of FOS in inflammation and calcification, its association with atherosclerosis severity has clear pathophysiologic bases as well as clinical implications as a marker. Our results suggest that analysis of gene expression in circulating cells may provide biological and clinical insights into human atherosclerosis, and that this type of approach may be applicable for studying other types of diseases.

1 January 2019 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
VKVadim S. Koshkin
Vadim S. Koshkin
JGJorge A. Garcia
Jorge A. Garcia
JRJordan P Reynolds
Jordan P Reynolds
PEPaul Elson
Paul Elson
CMCristina Magi-Galluzzi
Cristina Magi-Galluzzi
PGPetros Grivas
Petros Grivas
Purpose: Transcriptomic profiling can shed light on the biology of SCBC, nominating biomarkers and novel therapeutic targets. Experimental Design: Sixty-three SCBC patients had small cell histology confirmed and quantified by a genitourinary pathologist. Gene expression profiling was performed for 39 primary tumor samples, 1 metastatic sample, and 6 adjacent normal urothelium samples (46 total) from the same cohort. Protein levels of differentially expressed therapeutic targets, DLL3 and PDL1, and also CD56 and ASCL1, were confirmed by IHC. A SCBC PDX model was utilized to assess in vivo efficacy of DLL3-targeting antibody-drug conjugate (ADC). Results: Unsupervised hierarchical clustering of 46 samples produced 4 clusters that correlated with clinical phenotypes. Patients whose tumors had the most "normal-like" pattern of gene expression had longer OS compared to the other 3 clusters while patients with the most "metastasis-like" pattern had the shortest OS (p=0.047). Expression of DLL3, PDL1, ASCL1 and CD56 was confirmed by IHC in 68%, 30%, 52% and 81% of tissue samples, respectively. In a multivariate analysis, DLL3 protein expression on >10% and CD56 expression on >30% of tumor cells were both prognostic of shorter OS (p=0.03 each). A DLL3-targeting ADC showed durable anti-tumor efficacy in a SCBC PDX model. Conclusions: Gene expression patterns in SCBC are associated with distinct clinical phenotypes ranging from more indolent to aggressive disease. Overexpression of DLL3 mRNA and protein is common in SCBC and correlates with shorter OS. A DLL3-targeted ADC demonstrated in vivo efficacy superior to chemotherapy in a PDX model of SCBC.

8 October 2015 in The Prostate
Verified
Journal Article
Closed access
PDF file
OMOmar Y. Mian
Omar Y. Mian
MKMohamed H. Khattab
Mohamed H. Khattab
MHMohammad Hedayati
Mohammad Hedayati
JCJonathan Coulter
Jonathan Coulter
BSBudri Abubaker- Sharif
Budri Abubaker- Sharif
TDTheodore L. DeWeese
Theodore L. DeWeese

7 December 2020 in Blood Cancer Discovery
Verified
Journal Article
Closed access
PDF file
YGYihong Guan
Yihong Guan
ATAnand Dev Tiwari
Anand Dev Tiwari
JPJames G. Phillips
James G. Phillips
MHMetis Hasipek
Metis Hasipek
DGDale R. Grabowski
Dale R. Grabowski
Babal Kant JhaBabal Kant Jha
Babal Kant Jha
TET2 is frequently mutated in myeloid neoplasms. Genetic TET2 deficiency leads to skewed myeloid differentiation and clonal expansion, but minimal residual TET activity is critical for survival of neoplastic progenitor and stem cells. Consistent with mutual exclusivity of TET2 and neomorphic IDH1/2 mutations, here we report that IDH1/2 mutant–derived 2-hydroxyglutarate is synthetically lethal to TET dioxygenase–deficient cells. In addition, a TET-selective small-molecule inhibitor decreases cytosine hydroxymethylation and restricted clonal outgrowth of TET2 mutant but not normal hematopoietic precursor cells in vitro and in vivo. Although TET inhibitor phenocopied somatic TET2 mutations, its pharmacologic effects on normal stem cells are, unlike mutations, reversible. Treatment with TET inhibitor suppresses the clonal evolution of TET2-mutant cells in murine models and TET2-mutated human leukemia xenografts. These results suggest that TET inhibitors may constitute a new class of targeted agents in TET2-mutant neoplasia. Significance: Loss-of-function somatic TET2 mutations are among the most frequent lesions in myeloid neoplasms and associated disorders. Here we report a strategy for selective targeting of residual TET dioxygenase activity in TET-deficient clones that results in restriction of clonal evolution in vitro and in vivo.